Global Biodefense Market is valued at USD 13.43 Billion in 2021 and is expected to reach USD 20.47 Billion by 2028 with a CAGR of 6.2% over the forecast period.
Global Biodefense Market: Global Size, Trends, Competitive, Historical & Forecast Analysis to 2021-2027, The presence of favorable government initiatives, increasing investment by the governments in developed countries, and growing threat of terrorism across the globe are some of the major factors driving the growth of the Global Biodefense Market.
Biodefense is a system of planned actions to counter and reduce the risk of biological threats and to prepare, respond to, and recover from them if they happen. Biodefense involves the development of capabilities and knowledge to assess, detect, monitor, respond to, and attribute biological threats. Biodefense is frequently discussed in the context of Bioware or bioterrorism and is generally considered a military or emergency response term.
Biodefense applies to two distinct target populations: civilian non-combatant and military combatants (troops in the field). Biodefense uses medical measures to protect people against bioterrorism. This includes medicines and vaccinations. It also includes medical research and preparations to defend against bioterrorist attacks. It is technically possible to apply biodefense measures to protect animals or plants, but this is generally uneconomic.
The pandemic has also impacted the growth of the global biodefense market. The COVID-19 pandemic has witnessed the catastrophe of biological incidents which can cause substantial loss of life, economic damage, and require a whole-of-nation response involving multiple federal and non-federal entities. Covid-19 has increased the importance of biodefense and the interest of the associated authorities regarding it.
For example; on September 13th, 20221; San Angelo ISD installed a ‘bio-defense system’ to combat COVID-19 at middle school. And On June 25th, 2020; America’s top pandemic and biosecurity leaders announced the launch of the American BioDefense Institute, a Washington DC-based think tank that will offer research and advisory to the United States Congress, Federal Agency, and NGO space.
The key players of Global Biodefense Market are such as Cleveland BioLabs, Bavarian Nordic, Ichor Medical Systems, SIGA Technologies, Xoma Corporation, Achaogen, Inc., Emergent BioSolutions, Inc., DynPort Vaccine Company, LLC, Elusys Therapeutics, Inc., Dynavax Technologies Corporation, PharmAthene, Inc. and other
Global biodefense market is segmented on the basis of product type, application, and region. On the basis of type, the global biodefense market is segmented into anthrax, smallpox, botulism, radiation/nuclear, and others. On the basis of application, the global biodefense market is segmented into medical hygiene and national defense.
The regions covered in the Global Biodefense Market report are North America, Europe, Asia-Pacific, Latin America, and the Rest of the World. On the basis of country level, the market of Global Biodefense Market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
On June 25th, 2020; America’s top pandemic and biosecurity leaders announced the launch of the American BioDefense Institute, a Washington DC-based think tank that will offer research and advisory to the United States Congress, Federal Agency, and NGO space.
As Bioterrorism & other high consequence, biological events can result in issues such as epidemic illness, mass casualties, healthcare worker illness, environmental contamination, legal issues. It causes unease within the community and also in the medical community at large. Also, the bioterrorist attack has a lot in common with naturally occurring public health emergencies resulting from infectious diseases. So the biodefense has high demand as it cashes in on medical measures and uses vaccinations and medicines against bioterrorist attacks.
In addition, the presence of a significant number of key biodefense agencies such as the Defense (DOD), Departments of Homeland Security (DHS), Agriculture (USDA), Health and Human Services (HHS), and the Environmental Protection Agency in many regions across the globe are supplementing the market growth. These agencies conduct a wide range of activities for developing biological threat awareness for intentional & naturally occurring threats and report using that information to support investment decisions.
Furthermore, favorable government initiatives are also fostering market growth. For instance; The National Biodefense Analysis and Countermeasures Center (NBACC) is the first national laboratory created by the Department of Homeland Security. This NBACC reports unmet needs in homeland security & provides a continuously available national security, biocontainment laboratory capability for newly identified biological threats. This is also fueling the growth of the global biodefense market.
The global biodefense market is segmented into North America, Europe, Asia- Pacific Latin America and Middle East & Africa. North America is expected to dominate the global biodefense market due to the presence of high federal funding and technological advancements in this region. For instance; according to Federal Research and Development (R&D) Funding, in FY2017, about 8 federal agencies has received about 96.3% of total federal R&D funding, with the Department of Defense (39.3%) and the Department of Health and Human Services (27.3%) combined accounting for more than two-thirds of all federal R&D funding in the United States.
President Trump’s FY2019 budget is largely silent on funding levels for a number of multiagency R&D initiatives for biodefense. Also, the National Biodefense Strategy is aligned with the 2018 National Security Strategy of the United States. This strategy is to detect and contain biothreats at their source, support and promote biomedical innovation, and improve emergency response in case of biological outbreaks. Such government initiatives are driving the market for biodefense into this region.
Asia Pacific is expected to witness the fastest growth in the global biodefense market due to surging investments in R&D, the growing significance of biodefense, and the rising threat of harmful biological materials that produce emergencies in this region. There is growing investment in R&D for biodefense in the Asia Pacific region and Australia and Japan are two of the most established markets for biodefense in the region as there are well-established vaccines R&D and production facilities in these countries. Along with that, the presence of sophisticated healthcare infrastructure in the country contributes to its market position.
|2015 - 2020
|2021 - 2028
|Market Size in 2020:
|USD 13.43 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2027:
|USD 20.47 Billion
|Tables, Charts & Figures:
|Cleveland BioLabs, Bavarian Nordic, Ichor Medical Systems, SIGA Technologies, Xoma Corporation, Achaogen, Inc., Emergent BioSolutions, Inc., DynPort Vaccine Company, LLC, Elusys Therapeutics, Inc., Dynavax Technologies Corporation, PharmAthene, Inc. and other.
|By Types, By Application
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®